

Magseed®

The new *gold standard* in breast localisation

Meet the seed that *changed* the game

GLOBALLY

400K

Patients treated*

The Magseed® marker is a small metallic seed designed to accurately mark the site of breast cancer, allowing for precise removal during surgery.

Magseed is known worldwide as a simple and effective alternative to wire localisation. It's now the number one choice for thousands of clinicians and used in more countries than any other wire-free marker.

*Data on file at Endomag. Data correct as of March 2025



Small. Accurate. *Visible.*

Magseed is one of the smallest seed markers, placed with an 18G needle. Highly visible on ultrasound and X-ray, and detectable to the millimetre, Magseed guides you to your target with absolute precision[1].

Can't *move**, Won't *break*

Magseed can be implanted any time prior to surgery, where it will stay in place without risk of migration or deactivation[2]. It allows you to optimise schedules and eliminate delays to your start times.

Simple to remove

Magseed guides surgeons to the cancer, allowing you to remove only what you need to. Studies have shown it can deliver smaller specimens[3], reducing returns to the operating room.

[1] Boland et al (2023), [2] Harvey et al (2018), [3] Micha et al (2021),
*Data on file at Endomag. 0.01% migration rate in Endomag internal meta-analysis (090724) of clinical studies. Correct as of March 2025.

Working in *harmony*

Combining Magseed with the Magtrace® lymphatic tracer makes localisation and staging uniquely possible using just one platform, and just one probe.

Data shows this shortens operative times, achieves low re-excision rates and increases physician satisfaction[5].

[5] Pantiora et al (2023)

Trusted by *experts*, demanded by *patients*

Magseed has allowed thousands of clinicians around the world to take back control of their schedules and provide a better patient experience[3].

[3] Micha et al (2021)

Backed by *data*

Magseed is widely proven across an extensive library of over 100 published clinical studies, more than any other wire-free localisation device.

A prominent example is the 2023 multi-centre MagTOTAL RCT study, featuring the highest level of data recorded for any seed marker at the time of publication.

13,000+
Patients in clinical trials*

2.87%
Re-excision rate with the 'MagTOTAL' technique[5]

8.61%
Reduction in operative time[5]

9/10
Average clinician satisfaction rating across surgeons, radiologists and theatre coordinators[5]

*Data on file at Endomag. Data correct as of March 2025, [5] Pantiora et al (2023)

Sentimag. Magseed. Magtrace.

One platform.

Evaluate the full Sentimag® platform.

endomag.com/magseed

Technical specifications

Magseed®

General

Material	Medical grade stainless steel (low Nickel)
Seed size	1mm x 5mm – the smallest seed (volume) available
Deployment	End-deploy upon stylet depression
Indication	Long term and soft tissue
Needle length	7cm, 12cm
Needle gauge	18G – the slimmest introducer needle on the market
Imaging visibility	US, Mammo, Tomo, Stereo, CEDM

For more clinical data visit our website:

Scan QR



Sensing

Sensing type	Counts Mode
Sensing precision	+/- 1mm
Sensing depth	40mm
Sensing direction	360° – detectable from any angle
Different tissue types	Signal not attenuated by tissue type
Bracketing	20mm separation or greater

Reliability

Insertion	Cannot be broken
Accuracy	98% placement accuracy*
Robust	Cannot be damaged during placement or deactivated by electrocautery
Migration	Very low
Deactivation	Cannot be deactivated at implantation or in surgery
Interference	No interference from OR lights or surgeon headlamps
MRI	MRI conditional (1.5T and 3.0T)

*Data on file at Endomag. Endomag internal meta-analysis (090724) of clinical studies. Correct as of March 2025.

References

[1] Boland et al (2023) Isotropy of Seed Localisation for Breast-conserving Surgery – A Laboratory Assessment [Poster]. ASBrS Annual Meeting, 26-30 April 2023. John B. Hynes Veterans Memorial Convention Center, Boston

[2] Harvey et al (2018) Safety and feasibility of breast lesion localization using magnetic seed (Magseed): a multi-centre, open-label cohort study. Breast Cancer Res Treat. 2018 Jun;169(3):531-536. doi: 10.1007/s10549-018-4709-y

[3] Micha et al (2021), Patient and clinician satisfaction and clinical outcomes of Magseed compared with wire-guided localisation for impalpable breast lesions. Breast Cancer. 2021 Jan;28(1):196-205. doi: 10.1007/s12282-020-01149-1

[4] Gera et al (2020), Evolving Role of Magseed in Wireless Localization of Breast Lesions: Systematic Review and Pooled Analysis of 1,559 Procedures. Anticancer Res. 2020 Apr;40(4):1809-1815. doi: 10.21873/anticanres

[5] Pantiora et al (2023), Magnetic Seed vs Guidewire Breast Cancer Localization With Magnetic Lymph Node Detection: A Randomized Clinical Trial. JAMA Surg. 2024 Mar 1;159(3):239-246. doi: 10.1001/jamasurg

BR-MS-202505-303-UK

Important Safety Information: The Magtrace® lymphatic tracer and Sentimag® Magnetic Localisation System is indicated to assist in localising lymph nodes draining a tumour site, as part of a sentinel lymph node biopsy procedure (SLNB), in patients with breast cancer undergoing a mastectomy or lumpectomy. Magtrace® is contraindicated for known hypersensitivity to iron oxide or dextran compounds, Iron overload disease, a metal implant in the axilla or in the chest, SLNB before neoadjuvant chemotherapy (NAC) where magnetic resonance imaging (MRI) will be the primary imaging used for monitoring the progress of NAC, patients identified in advance to require post-lumpectomy imaging with breast MRI. For a complete list of warnings and precautions, please see the Instructions for use for the device.

The Endomag Magseed® Magnetic Marker is indicated for use to radiographically mark soft tissue during a surgical procedure or for future surgical procedures. Using imaging guidance such as ultrasound or radiography or aided by non-imaging guidance (Endomag Sentimag® System) the marker is located and surgically removed with the target tissue. The Endomag Sentimag® System is the only non-imaging guidance system intended for use with the Magseed® Magnetic Marker. The Endomag Magseed® is not intended for use in the central nervous system, circulatory system, heart, eyes or brain. The device should not be placed in a tissue site with clinical evidence of infection. For a complete list of warnings and precautions, please see the Instructions for use for the device.

The Sentimag® Magnetic Localisation System when used with the Magseed® is indicated to assist in localising soft tissue lesions. The Endomag Sentimag® System is the only non-imaging guidance system intended for use with the Magseed® magnetic marker. The device is not intended for use in the central nervous system, circulatory system, heart, eyes or brain. The device should not be placed in a tissue site with clinical evidence of infection. For a complete list of warnings and precautions, please see the Instructions for use for the device.

MLCO disclaimer: This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com

Endomagnetics Ltd (Endomag).
Registered in England and Wales
(No. 06227698).

330 Cambridge Science Park,
Milton Road, Cambridge,
CB4 0WN, United Kingdom

info@endomag.com
+44 1223 652540
endomag.com

endomag
A Hologic Company